PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 154 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 1.56 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $147,000 | – | 19,919 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 6,158,000 | $38,611,000 | 2.32% |
| ARDSLEY ADVISORY PARTNERS LP | 2,045,000 | $12,822,000 | 1.73% |
| RA Capital Management | 3,030,303 | $19,000,000 | 1.02% |
| Phocas Financial Corp. | 1,736,386 | $10,887,000 | 0.95% |
| ARDSLEY ADVISORY PARTNERS LP | 500,000 | $3,135,000 | 0.42% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,345,260 | $8,435,000 | 0.30% |
| BKS ADVISORS, LLC | 115,115 | $721,000 | 0.26% |
| PINNACLE ASSOCIATES LTD | 1,530,657 | $9,597,000 | 0.20% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $24,745,000 | 0.18% |
| EAGLE ASSET MANAGEMENT INC | 4,444,673 | $27,868,000 | 0.14% |